What is UZEDY used for?
UZEDY (risperidone) is an extended-release injectable antipsychotic approved by the FDA for treating schizophrenia in adults. It delivers medication monthly or every two months via subcutaneous injection, helping manage symptoms like hallucinations, delusions, and disorganized thinking common in this mental health disorder.[1]
How does UZEDY treat schizophrenia?
Risperidone works by balancing dopamine and serotonin levels in the brain, reducing psychotic symptoms and stabilizing mood. Clinical trials showed it matches oral risperidone's effectiveness while improving adherence due to less frequent dosing—no daily pills needed.[1][2]
Is UZEDY approved for other mental health conditions?
No, UZEDY's FDA label limits it to schizophrenia. Oral risperidone treats bipolar mania and irritability in autism, but UZEDY lacks those approvals. Off-label use for other conditions like bipolar disorder occurs but isn't FDA-endorsed.[1][3]
What are common side effects and risks?
Patients report weight gain, drowsiness, injection-site reactions, and movement disorders like tremors. Long-term risks include elevated blood sugar, high cholesterol, and tardive dyskinesia. It's not for elderly dementia patients due to increased death risk from heart issues or infections.[1][2]
How does UZEDY compare to other schizophrenia treatments?
Unlike daily oral antipsychotics (e.g., Risperdal), UZEDY offers steady release for better compliance. Competitors like Invega Hafyera (paliperidone) provide six-month dosing. It's pricier upfront (~$2,000-$3,000 per injection) but may cut long-term costs via fewer clinic visits.[2][4]
Who makes UZEDY and what's the patent status?
Teva Pharmaceuticals and MedinCell developed UZEDY, launched in 2023. Key patents cover the Steady-state Technology delivery system, with U.S. Patent No. 10,987,410 expiring around 2038—check DrugPatentWatch.com for litigation updates and generics timeline.[5]
[1]: FDA Label - UZEDY (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212385s000lbl.pdf)
[2]: Teva Press Release (https://www.tevapharm.com/news-and-events/press-releases/2023/apr/teva-and-medincell-announce-fda-approval-of-uzedy/)
[3]: Drugs.com - Risperidone Uses (https://www.drugs.com/risperidone.html)
[4]: GoodRx Pricing Data (https://www.goodrx.com/uzedy)
[5]: DrugPatentWatch.com - UZEDY Patents (https://www.drugpatentwatch.com/p/tradename/UZEDY)